Kymera Therapeutics (NASDAQ:KYMR) CFO Sells $3,961,000.00 in Stock

Key Points

• Bruce Jacobs, CFO of Kymera Therapeutics, sold 79,220 shares for approximately $3.96 million, resulting in a 25.84% decrease in his ownership.
• Kymera reported a loss of $0.95 per share for the last quarter, missing analysts' estimates, and experienced a 55.1% decline in revenue year-over-year.
• Research analysts have a consensus rating of “Buy” for Kymera Therapeutics, with an average price target of $59.42, indicating positive sentiment despite recent challenges.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CFO Bruce N. Jacobs sold 79,220 shares of Kymera Therapeutics stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total value of $3,961,000.00. Following the sale, the chief financial officer owned 227,409 shares in the company, valued at $11,370,450. This trade represents a 25.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Kymera Therapeutics Trading Down 4.0%

Shares of Kymera Therapeutics stock traded down $2.03 during trading hours on Friday, hitting $49.13. 2,555,812 shares of the company's stock traded hands, compared to its average volume of 789,971. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $53.27. The company has a fifty day simple moving average of $43.85 and a 200-day simple moving average of $37.92.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. Kymera Therapeutics's quarterly revenue was down 55.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.58) EPS. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its position in Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after buying an additional 689,547 shares during the last quarter. BVF Inc. IL raised its stake in shares of Kymera Therapeutics by 6.6% during the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company's stock worth $240,138,000 after acquiring an additional 340,909 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after acquiring an additional 344,080 shares in the last quarter. Siren L.L.C. lifted its holdings in shares of Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock worth $88,687,000 after acquiring an additional 270,580 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Kymera Therapeutics by 5.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company's stock valued at $52,075,000 after purchasing an additional 59,347 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target on the stock in a report on Monday, June 2nd. Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the company a "buy" rating in a research note on Wednesday, June 25th. BTIG Research reaffirmed a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 26th. HC Wainwright lifted their price objective on Kymera Therapeutics from $60.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Morgan Stanley assumed coverage on shares of Kymera Therapeutics in a report on Thursday, July 3rd. They set an "overweight" rating and a $70.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of "Buy" and an average target price of $59.95.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.